Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025

Rhea-AI Summary

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotech company focused on cell therapies for autoimmune diseases and cancers, will participate in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.

The presentation will be accessible through a live webcast in the "Investors" section of Artivabio.com, with the replay available for 90 days after the event. Management will also be available for meetings with registered conference attendees.

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:45 a.m. EDT.

Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference.

Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases. This includes two company-sponsored trials, a trial in systemic lupus erythematosus for patients with or without lupus nephritis and a basket trial across autoimmune diseases including rheumatoid arthritis and Sjögren’s disease, as well as an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs. 

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com 
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com 

Source: Artiva Biotherapeutics, Inc.

FAQ

When is Artiva Biotherapeutics (ARTV) presenting at the Cantor Global Healthcare Conference 2025?

Artiva Biotherapeutics will present in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.

How can investors access Artiva Biotherapeutics' (ARTV) Cantor conference presentation?

Investors can access the live webcast through the 'Investors' section on Artivabio.com. A replay will be available for 90 days following the event.

What type of therapies is Artiva Biotherapeutics (ARTV) developing?

Artiva Biotherapeutics is developing cell therapies for patients with autoimmune diseases and cancers, focusing on effective, safe, and accessible treatments.

Will Artiva Biotherapeutics (ARTV) management be available for investor meetings at the Cantor conference?

Yes, members of the Artiva management team will be available for meetings with investors who are registered to attend the conference.